UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 6, 2009
AngioDynamics, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50761 11-3146460
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File (IRS Employer
of Incorporation) Number) Identification No.)
603 Queensbury Avenue, Queensbury, New York 12804
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(518) 798-1215
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2 (b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4 (c))
Item 2.02 - Results of Operations and Financial Condition.
On October 6, 2009, AngioDynamics, Inc. (the "Company") issued a press
release announcing financial results for the fiscal first quarter ended August
31, 2009.
The information set forth in Item 2.02 of this Form 8-K (including Exhibit
99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such a filing.
Forward-Looking Statements
This document and its attachments include "forward-looking statements"
intended to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Investors can identify these
statements by the fact that they do not relate strictly to historical or current
facts. These statements contain words such as "expect," "reaffirm,"
"anticipate," "plan," "believe," "estimate," "may," "will," "predict,"
"project," "might," "intend," "potential," "could," "would," "should,"
"estimate," "seek," "continue," "pursue," or "our future success depends," or
the negative or other variations thereof or comparable terminology, are intended
to identify such forward-looking statements. In particular, they include
statements relating to, among other things, future actions, strategies, future
performance and future financial results of the Company. These forward-looking
statements are based on current expectations and projections about future
events.
Investors are cautioned that forward-looking statements are not
guarantees of future performance or results and involve risks and uncertainties
that cannot be predicted or quantified and, consequently, the actual performance
or results of the Company may differ materially from those expressed or implied
by such forward-looking statements. Such risks and uncertainties include, but
are not limited to, the factors described from time to time in the Company's
reports filed with the SEC, including the Company's Form 10-K for the fiscal
year ended May 31, 2009, financial community and rating agency perceptions of
the Company; the effects of economic, credit and capital market conditions on
the economy in general, and on medical device companies in particular; domestic
and foreign health care reforms and governmental laws and regulations;
third-party relations and approvals, technological advances and patents attained
by competitors; and challenges inherent in new product development, including
obtaining regulatory approvals. In addition to the matters described above, the
ability of the Company to develop its products, future actions by the FDA or
other regulatory agencies, results of pending or future clinical trials, the
outcome of pending patent litigation, overall economic conditions, general
market conditions, market acceptance, foreign currency exchange rate
fluctuations, and the effects on pricing from group purchasing organizations and
competition and the ability of the Company to integrate purchased businesses,
may affect the actual results achieved by the Company.
Any forward-looking statements are made pursuant to the Private
Securities Litigation Reform Act of 1995 and, as such, speak only as of the date
made. The Company disclaims any obligation to update the forward-looking
statements. Investors are cautioned not to place undue reliance on these
forward-looking statements which speak only as of the date stated, or if no date
is stated, as of the date of this document.
Item 9.01 - Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
- ----------- -----------
99.1 Press Release dated October 6, 2009.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANGIODYNAMICS, INC.
(Registrant)
Date: October 6, 2009 By: /s/ D. Joseph Gersuk
-------------------------------
D. Joseph Gersuk
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press Release dated October 6, 2009.